I'm not counting any chickens or revenue, but we are talking about an estimate of revenue, are we not? If we are to believe management's statements about their involvement with Alzheimer's researchers and key opinion leaders, and their statements that they are very pleased with the 80%+ accuracy using a single biomarker, then one could reasonably conclude that perhaps a 10% capture of the $150M RUO market is not unreasonable for the first year of commercialization. $1M seems to be a prediction based on what, less than 1% capture? Sorry, it doesn't pass the reasonable expectation in my book.